Invion Limited (ASX: IVX)
Health Care · Pharmaceuticals · AU
AU$0.04
-7.50% today · -69.2% 1Y
Invion Limited (ASX: IVX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.90M and employs 8 people.
Over the last twelve months the share price has lost 69.2%, trading between 0.03 and 0.14.
Tweenvest scores Invion Limited across four factors: quality 40/100. Its strongest factor is quality.
IVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.90M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.13
- Dividend yield
- —
- Beta (5Y)
- 0.43
- 52-week high
- AU$0.14
- 52-week low
- AU$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 109.20M
- Employees
- 8
- Next earnings
- —
About Invion Limited
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
- ISIN
- AU000000IVX4
- Founded
- 2000
- Listed since
- Feb 14, 2010
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.